Advancing Cell Therapy for Cardiovascular Disease
In this GEN webinar, our expert speaker Joshua Michael Hare, MD, will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular disease. The post Advancing Cell Therapy for Cardiovascular Disease appeared first on GEN - Genetic Engineering and Biotechnology News .
Joshua Michael Hare, MD, a board-certified cardiologist and founding director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine, has made significant contributions to the field of regenerative medicine. With over 450 published articles to his name, Hare has focused his research on using cells as medicines for various human diseases, including heart disease, Alzheimer’s, stroke, and aging-related conditions.
His work has received funding from prestigious sources such as the National Institutes of Health and the Department of Defense. Hare has overseen numerous clinical trials exploring cell and gene therapy for ischemic and non-ischemic cardiomyopathy. During the GEN webinar "Advancing Cell Therapy for Cardiovascular Disease," Hare will delve into the potential of regenerative and cellular therapies for repairing damaged heart tissue, promoting vascularization, modulating inflammation, and restoring cardiac function.
The presentation will discuss the critical aspects of translating research advancements into practical therapeutics, including choosing appropriate cell types, indications, and treatment strategies based on disease pathophysiology and clinical needs. Hare will also address the journey from laboratory research to clinical investigation, covering aspects such as cell delivery methods, patient selection, and the essential clinical endpoints to assess safety and therapeutic effectiveness.
Following the talk, attendees will have the opportunity to engage in a live Q&A session with Hare, allowing them to ask questions and gain deeper insights into the subject matter. This webinar is made possible with the support of The GEN.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
